Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “AIDS Vaccines”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00574600
What this trial is testing

Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 48
Early research (Phase 1)UnknownNCT04553016
What this trial is testing

Test Three Experimental HIV Vaccines in Healthy Adults.

Who this might be right for
HIV-1-infection
University of Oxford 88
Large-scale testing (Phase 3)UnknownNCT01289106
What this trial is testing

Modified Dose and Schedule of Recombinant Hepatitis B Vaccination in HIV-infected Adult Subjects

Who this might be right for
HIV Infection
Chiang Mai University 132
Early research (Phase 1)Study completedNCT00000884
What this trial is testing

Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 84
Large-scale testing (Phase 3)Study completedNCT01527825
What this trial is testing

Immunogenicity and Safety of Different Dosing Schedules of Trivalent Influenza Vaccine in HIV-infected Pregnant Women

Who this might be right for
Influenza
University of Witwatersrand, South Africa 800
Testing effectiveness (Phase 2)Study completedNCT00339040
What this trial is testing

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

Who this might be right for
HIV InfectionsSexually Transmitted Diseases
National Institute of Allergy and Infectious Diseases (NIAID) 130
Early research (Phase 1)Study completedNCT01989533
What this trial is testing

Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers

Who this might be right for
Vaccine Response
National Institute of Allergy and Infectious Diseases (NIAID) 62
Early research (Phase 1)Study completedNCT00001538
What this trial is testing

Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers

Who this might be right for
Acquired Immunodeficiency SyndromeHIV Infection
National Institute of Allergy and Infectious Diseases (NIAID) 41
Testing effectiveness (Phase 2)Looking for participantsNCT06599658
What this trial is testing

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

Who this might be right for
COVID 19InfluenzaRheumatoid Arthritis (RA)+5 more
McGill University Health Centre/Research Institute of the McGill University Health Centre 660
Early research (Phase 1)UnknownNCT01428596
What this trial is testing

Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects

Who this might be right for
HIV Infections
GeneCure Biotechnologies 30
Post-approval studies (Phase 4)Study completedNCT01138215
What this trial is testing

The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children

Who this might be right for
HIV InfectionsVaricella-zoster Virus
The HIV Netherlands Australia Thailand Research Collaboration 60
Testing effectiveness (Phase 2)WithdrawnNCT05539989
What this trial is testing

Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa

Who this might be right for
TuberculosisHIV Infections
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Not applicableWithdrawnNCT00000835
What this trial is testing

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
Testing effectiveness (Phase 2)Study completedNCT00189904
What this trial is testing

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients

Who this might be right for
HIV Infections
Bavarian Nordic 151
Not applicableUnknownNCT03804489
What this trial is testing

Using "Decision Aids" to Help the Infant Family to Decide the Use of Oral Rotavirus Vaccine

Who this might be right for
Rotavirus Vaccines
Taipei Medical University Shuang Ho Hospital 180
Not applicableLooking for participantsNCT06885853
What this trial is testing

Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine

Who this might be right for
Monkeypox
Assistance Publique - Hôpitaux de Paris 90
Early research (Phase 1)UnknownNCT05772286
What this trial is testing

Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine, Adjuvanted With MPLA Liposomes, in Healthy, HIV-Uninfected Adults

Who this might be right for
Healthy
Fundacion Clinic per a la Recerca Biomédica 12
Testing effectiveness (Phase 2)Study completedNCT00137605
What this trial is testing

Early Versus Delayed Pneumococcal Vaccination in HIV

Who this might be right for
Pneumococcal Infections
CIHR Canadian HIV Trials Network 79
Large-scale testing (Phase 3)Study completedNCT00006327
What this trial is testing

Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand

Who this might be right for
HIV InfectionsHIV Seronegativity
VaxGen 2,500
Early research (Phase 1)Study completedNCT00000745
What this trial is testing

A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 72
Next Page